Such allegations were reflected in yesterday’s trading, as Krka’s share price decreased by 4.42%, closing at EUR 73.6 per share.

According to unconfirmed media reports, Krka is under investigation by the Romanian health ministry after confidential documents detailing controversial payments to doctors were leaked to the local media.  Romanian media released certain documents and testimonials from employees claiming that Krka also bribed doctors for prescribing Biobil.

Such allegations were reflected in yesterday’s trading, as Krka’s share price decreased by 4.42%, closing at EUR 73.6 per share. Excluding ex-dividend dates, this is the highest daily share price decrease since January 2013. It is worth noting that Romanian market accounts for roughly EUR 53m of Krka’s sales (roughly 4% of FY 2018 sales).

Earlier today, Krka published an official statement regarding the mentioned issue. To read more about their statement click here.